Integrated material-generation strategies pair stable expression systems with optimized platforms to produce high-quality proteins faster. The result: better scalability, less variability, reliable early developability assessments, and a smoother transition to manufacturing.
See how tighter alignment between vector construction and cell banking compressed the path to IND — improving efficiency, strengthening risk management, and making an aggressive nine-month timeline achievable without compromising quality.
A smarter approach to downstream processing can cut timelines and costs without sacrificing quality. This white paper looks at how to build purification processes that stay robust and reproducible when they scale to manufacturing.
Samsung Biologics is a fully integrated, end-to-end CDMO partner offering seamless development and manufacturing services from cell line development to final aseptic fill/finish for biologics. Keeping the highest standards of commercialization in mind, we continue to expand our development portfolio and continue to offer the most optimized service to fit clients' needs. Our facilities are cGMP compliant with bioreactor sizes ranging from small to large scale, enabling us to better serve the various needs of our clients and to meet growing biomanufacturing demands.
